American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

BioAge Labs, Inc. (BIOA)

$5.10 -7.78% NASDAQ: BIOA · 15-min delayed

EMERYVILLE, California
Public · NASDAQ: BIOA
62 employees

Visit website Follow

$967.7MMarket cap

$9.0MRevenue · FY2025

-$80.6MNet income

62Employees

BIOANASDAQ

2024IPO

About BioAge Labs, Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: BIOA
Employees: 62
IPO date: Sep 26, 2024
Headquarters: 5885 HOLLIS STREET
EMERYVILLE, California 94608
Phone: 510-806-1445
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Newark, US
Legal entity ID: 529900NG0C40250Z7875

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: BIOA Nasdaq
SEC CIK: 1709941
LEI: 529900NG0C40250Z7875
EIN: 474721157
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show BioAge Labs, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/bioage-labs-inc/"><img src="https://americancompanies.com/badge/bioage-labs-inc.svg" alt="BioAge Labs, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BioAge Labs, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $9.0M
Net income: -$80.6M
Total assets: $294.9M
Market cap: $967.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BIOA

$5.10 -7.78%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.84 $25.10

52-week range

Market cap: $967.7M
Shares outstanding: 189.8M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Sep 26, 2024

BioAge Labs, Inc. (BIOA) Stock Price

Reported a net loss of $80.6M in FY2025.
Trading 80% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BioAge Labs, Inc..

Write a review

Newsroom

News about BioAge Labs, Inc.

BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire Inc. · 2026-09-02 · positive BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire Inc. · 2026-08-05 · positive BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk GlobeNewswire Inc. · 2026-06-16 · positive BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire Inc. · 2026-05-22 · positive Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Benzinga · 2026-05-20 · positive BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP GlobeNewswire Inc. · 2026-04-21 · positive

News & sentiment via Polygon.io

FAQ

BioAge Labs, Inc.: frequently asked questions

Is BioAge Labs, Inc. an American company?

BioAge Labs, Inc. is a US-based company headquartered in Emeryville, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is BioAge Labs, Inc. headquartered?

BioAge Labs, Inc. is headquartered in Emeryville, California, United States.

Is BioAge Labs, Inc. publicly traded?

Yes — BioAge Labs, Inc. is a publicly traded company. Its stock trades under the ticker symbol BIOA on the NASDAQ.

What does BioAge Labs, Inc. do?

BioAge Labs, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore